Natixis Advisors L.P. Buys 6,204 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Natixis Advisors L.P. raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 4.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 150,825 shares of the medical equipment provider's stock after purchasing an additional 6,204 shares during the quarter. Natixis Advisors L.P. owned 0.07% of Zimmer Biomet worth $18,355,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. American Century Companies Inc. lifted its stake in Zimmer Biomet by 21.2% in the 3rd quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider's stock worth $545,809,000 after purchasing an additional 852,186 shares in the last quarter. Boston Partners grew its position in Zimmer Biomet by 29.2% in the 3rd quarter. Boston Partners now owns 2,694,832 shares of the medical equipment provider's stock valued at $302,366,000 after acquiring an additional 608,959 shares during the last quarter. Barclays PLC lifted its stake in shares of Zimmer Biomet by 129.2% during the 3rd quarter. Barclays PLC now owns 1,072,494 shares of the medical equipment provider's stock worth $120,356,000 after purchasing an additional 604,652 shares during the last quarter. Van ECK Associates Corp lifted its stake in shares of Zimmer Biomet by 23.7% during the 4th quarter. Van ECK Associates Corp now owns 2,838,558 shares of the medical equipment provider's stock worth $345,452,000 after purchasing an additional 543,344 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new stake in Zimmer Biomet in the third quarter valued at about $57,972,000. 88.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the company's stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the transaction, the vice president now directly owns 44,145 shares of the company's stock, valued at $5,677,929.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.70% of the company's stock.

Zimmer Biomet Price Performance

ZBH traded down $1.09 during trading on Monday, reaching $120.57. The stock had a trading volume of 1,293,796 shares, compared to its average volume of 1,480,384. The firm has a market capitalization of $24.80 billion, a price-to-earnings ratio of 26.33, a price-to-earnings-growth ratio of 2.23 and a beta of 1.03. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $147.50. The stock has a 50 day moving average of $125.30 and a two-hundred day moving average of $120.21.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, topping analysts' consensus estimates of $1.87 by $0.07. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The firm's revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.89 earnings per share. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.80%. The ex-dividend date of this dividend was Wednesday, March 27th. Zimmer Biomet's dividend payout ratio (DPR) is currently 20.78%.

Wall Street Analyst Weigh In

Several analysts recently commented on ZBH shares. JPMorgan Chase & Co. raised their target price on Zimmer Biomet from $115.00 to $125.00 and gave the stock a "neutral" rating in a report on Friday, February 9th. TheStreet raised Zimmer Biomet from a "c" rating to a "b-" rating in a report on Thursday, February 8th. Barclays raised their target price on Zimmer Biomet from $120.00 to $130.00 and gave the company an "underweight" rating in a research report on Monday, February 12th. Truist Financial decreased their target price on Zimmer Biomet from $137.00 to $130.00 and set a "hold" rating on the stock in a research report on Friday. Finally, StockNews.com downgraded Zimmer Biomet from a "strong-buy" rating to a "buy" rating in a research report on Monday, February 19th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $135.40.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.